Amring Pharmaceuticals Names Jai G. Parekh, MD, Chief Commercial Officer, Eye Care, US

Amring Pharmaceuticals, a subsidiary of Nordic Group BV, has named Jai G. Parekh, MD, MBA, as Chief Commercial Officer, Eye Care, US. 

Nordic Pharma recently expanded its pharmaceutical presence in the US by acquiring Visant Medical, maker of the FDA-cleared hyaluronic acid derivative Lacrifill, a canalicular occlusive device, intended to temporarily block tear drainage by the occlusion of the canalicular system. 

“With this exciting acquisition and our global plans for Lacrifill, Dr. Parekh’s 25 years of eye care experience, strategic leadership, and deep understanding of eye care and the industry make him the perfect choice to guide our commercial entry into the US market,” Charlotte Phelps, CEO, Nordic Pharma, said in a company news release. “As a practicing ophthalmologist, Dr. Parekh’s patient-driven focus will also be invaluable for making a sustainable impact on the health of people with dry eye disease.”

“I am honored to be a part of Nordic Pharma, a company known for its commitment to innovation and improving patient outcomes,” said Dr. Parekh. “I look forward to contributing to the growth and success of the organization by helping lead impactful commercial strategies. There are many ways to take care of dry eye patients and with this huge market opportunity, we believe Lacrifill will be a significant part of the armamentaria.”

In addition to Dr. Parekh’s appointment, Nordic Pharma has formed its US Medical Advisory Board, which includes Richard Lindstrom, MD (Minnesota); Vance Thompson, MD (South Dakota); Preeya Gupta, MD (North Carolina); Paul Karpecki, OD (Kentucky); Lisa Nijm, MD, JD (Illinois); and Selina McGee, OD (Oklahoma). Also, following the Visant Medical acquisition, Andy Corley of Yelroc Consulting joined as a commercial advisor to Nordic Pharma.